Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients

Monique Maas, Patty J. Nelemans, Vincenzo Valentini, Christopher H. Crane, Carlo Capirci, Claus Rödel, Garrett M. Nash, Li-Jen Kuo, Rob Glynne-Jones, Julio García-Aguilar, Javier Suárez, Felipe A. Calvo, Salvatore Pucciarelli, Sebastiano Biondo, George Theodoropoulos, Doenja M J Lambregts, Regina G H Beets-Tan, Geerard L. Beets

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Recent literature suggests that the benefit of adjuvant chemotherapy (aCT) for rectal cancer patients might depend on the response to neoadjuvant chemoradiation (CRT). Aim was to evaluate whether the effect of aCT in rectal cancer is modified by response to CRT and to identify which patients benefit from aCT after CRT, by means of a pooled analysis of individual patient data from 13 datasets. Patients were categorized into three groups: pCR (ypT0N0), ypT1-2 tumour and ypT3-4 tumour. Hazard ratios (HR) for the effect of aCT were derived from multivariable Cox regression analyses. Primary outcome measure was recurrence-free survival (RFS). One thousand seven hundred and twenty three (1723) (52%) of 3,313 included patients received aCT. Eight hundred and ninety eight (898) patients had a pCR, 966 had a ypT1-2 tumour and 1,302 had a ypT3-4 tumour. For 122 patients response, category was missing and 25 patients had ypT0N+. Median follow-up for all patients was 51 (0-219) months. HR for RFS with 95% CI for patients treated with aCT were 1.25(0.68-2.29), 0.58(0.37-0.89) and 0.83(0.66-1.10) for patients with pCR, ypT1-2 and ypT3-4 tumours, respectively. The effect of aCT in rectal cancer patients treated with CRT differs between subgroups. Patients with a pCR after CRT may not benefit from aCT, whereas patients with residual tumour had superior outcomes when aCT was administered. The test for interaction did not reach statistical significance, but the results support further investigation of a more individualized approach to administer aCT after CRT and surgery based on pathologic staging.

Original languageEnglish
Pages (from-to)212-220
Number of pages9
JournalInternational Journal of Cancer
Volume137
Issue number1
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Adjuvant Chemotherapy
Rectal Neoplasms
Neoplasms
Recurrence
Survival
Residual Neoplasm
Regression Analysis

Keywords

  • adjuvant chemotherapy
  • neoadjuvant treatment
  • rectal cancer
  • response
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Adjuvant chemotherapy in rectal cancer : Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. / Maas, Monique; Nelemans, Patty J.; Valentini, Vincenzo; Crane, Christopher H.; Capirci, Carlo; Rödel, Claus; Nash, Garrett M.; Kuo, Li-Jen; Glynne-Jones, Rob; García-Aguilar, Julio; Suárez, Javier; Calvo, Felipe A.; Pucciarelli, Salvatore; Biondo, Sebastiano; Theodoropoulos, George; Lambregts, Doenja M J; Beets-Tan, Regina G H; Beets, Geerard L.

In: International Journal of Cancer, Vol. 137, No. 1, 01.07.2015, p. 212-220.

Research output: Contribution to journalArticle

Maas, M, Nelemans, PJ, Valentini, V, Crane, CH, Capirci, C, Rödel, C, Nash, GM, Kuo, L-J, Glynne-Jones, R, García-Aguilar, J, Suárez, J, Calvo, FA, Pucciarelli, S, Biondo, S, Theodoropoulos, G, Lambregts, DMJ, Beets-Tan, RGH & Beets, GL 2015, 'Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients', International Journal of Cancer, vol. 137, no. 1, pp. 212-220. https://doi.org/10.1002/ijc.29355
Maas, Monique ; Nelemans, Patty J. ; Valentini, Vincenzo ; Crane, Christopher H. ; Capirci, Carlo ; Rödel, Claus ; Nash, Garrett M. ; Kuo, Li-Jen ; Glynne-Jones, Rob ; García-Aguilar, Julio ; Suárez, Javier ; Calvo, Felipe A. ; Pucciarelli, Salvatore ; Biondo, Sebastiano ; Theodoropoulos, George ; Lambregts, Doenja M J ; Beets-Tan, Regina G H ; Beets, Geerard L. / Adjuvant chemotherapy in rectal cancer : Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. In: International Journal of Cancer. 2015 ; Vol. 137, No. 1. pp. 212-220.
@article{d118839c99d349838bf0a3f7bf63d357,
title = "Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients",
abstract = "Recent literature suggests that the benefit of adjuvant chemotherapy (aCT) for rectal cancer patients might depend on the response to neoadjuvant chemoradiation (CRT). Aim was to evaluate whether the effect of aCT in rectal cancer is modified by response to CRT and to identify which patients benefit from aCT after CRT, by means of a pooled analysis of individual patient data from 13 datasets. Patients were categorized into three groups: pCR (ypT0N0), ypT1-2 tumour and ypT3-4 tumour. Hazard ratios (HR) for the effect of aCT were derived from multivariable Cox regression analyses. Primary outcome measure was recurrence-free survival (RFS). One thousand seven hundred and twenty three (1723) (52{\%}) of 3,313 included patients received aCT. Eight hundred and ninety eight (898) patients had a pCR, 966 had a ypT1-2 tumour and 1,302 had a ypT3-4 tumour. For 122 patients response, category was missing and 25 patients had ypT0N+. Median follow-up for all patients was 51 (0-219) months. HR for RFS with 95{\%} CI for patients treated with aCT were 1.25(0.68-2.29), 0.58(0.37-0.89) and 0.83(0.66-1.10) for patients with pCR, ypT1-2 and ypT3-4 tumours, respectively. The effect of aCT in rectal cancer patients treated with CRT differs between subgroups. Patients with a pCR after CRT may not benefit from aCT, whereas patients with residual tumour had superior outcomes when aCT was administered. The test for interaction did not reach statistical significance, but the results support further investigation of a more individualized approach to administer aCT after CRT and surgery based on pathologic staging.",
keywords = "adjuvant chemotherapy, neoadjuvant treatment, rectal cancer, response, survival",
author = "Monique Maas and Nelemans, {Patty J.} and Vincenzo Valentini and Crane, {Christopher H.} and Carlo Capirci and Claus R{\"o}del and Nash, {Garrett M.} and Li-Jen Kuo and Rob Glynne-Jones and Julio Garc{\'i}a-Aguilar and Javier Su{\'a}rez and Calvo, {Felipe A.} and Salvatore Pucciarelli and Sebastiano Biondo and George Theodoropoulos and Lambregts, {Doenja M J} and Beets-Tan, {Regina G H} and Beets, {Geerard L.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/ijc.29355",
language = "English",
volume = "137",
pages = "212--220",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Adjuvant chemotherapy in rectal cancer

T2 - Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients

AU - Maas, Monique

AU - Nelemans, Patty J.

AU - Valentini, Vincenzo

AU - Crane, Christopher H.

AU - Capirci, Carlo

AU - Rödel, Claus

AU - Nash, Garrett M.

AU - Kuo, Li-Jen

AU - Glynne-Jones, Rob

AU - García-Aguilar, Julio

AU - Suárez, Javier

AU - Calvo, Felipe A.

AU - Pucciarelli, Salvatore

AU - Biondo, Sebastiano

AU - Theodoropoulos, George

AU - Lambregts, Doenja M J

AU - Beets-Tan, Regina G H

AU - Beets, Geerard L.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Recent literature suggests that the benefit of adjuvant chemotherapy (aCT) for rectal cancer patients might depend on the response to neoadjuvant chemoradiation (CRT). Aim was to evaluate whether the effect of aCT in rectal cancer is modified by response to CRT and to identify which patients benefit from aCT after CRT, by means of a pooled analysis of individual patient data from 13 datasets. Patients were categorized into three groups: pCR (ypT0N0), ypT1-2 tumour and ypT3-4 tumour. Hazard ratios (HR) for the effect of aCT were derived from multivariable Cox regression analyses. Primary outcome measure was recurrence-free survival (RFS). One thousand seven hundred and twenty three (1723) (52%) of 3,313 included patients received aCT. Eight hundred and ninety eight (898) patients had a pCR, 966 had a ypT1-2 tumour and 1,302 had a ypT3-4 tumour. For 122 patients response, category was missing and 25 patients had ypT0N+. Median follow-up for all patients was 51 (0-219) months. HR for RFS with 95% CI for patients treated with aCT were 1.25(0.68-2.29), 0.58(0.37-0.89) and 0.83(0.66-1.10) for patients with pCR, ypT1-2 and ypT3-4 tumours, respectively. The effect of aCT in rectal cancer patients treated with CRT differs between subgroups. Patients with a pCR after CRT may not benefit from aCT, whereas patients with residual tumour had superior outcomes when aCT was administered. The test for interaction did not reach statistical significance, but the results support further investigation of a more individualized approach to administer aCT after CRT and surgery based on pathologic staging.

AB - Recent literature suggests that the benefit of adjuvant chemotherapy (aCT) for rectal cancer patients might depend on the response to neoadjuvant chemoradiation (CRT). Aim was to evaluate whether the effect of aCT in rectal cancer is modified by response to CRT and to identify which patients benefit from aCT after CRT, by means of a pooled analysis of individual patient data from 13 datasets. Patients were categorized into three groups: pCR (ypT0N0), ypT1-2 tumour and ypT3-4 tumour. Hazard ratios (HR) for the effect of aCT were derived from multivariable Cox regression analyses. Primary outcome measure was recurrence-free survival (RFS). One thousand seven hundred and twenty three (1723) (52%) of 3,313 included patients received aCT. Eight hundred and ninety eight (898) patients had a pCR, 966 had a ypT1-2 tumour and 1,302 had a ypT3-4 tumour. For 122 patients response, category was missing and 25 patients had ypT0N+. Median follow-up for all patients was 51 (0-219) months. HR for RFS with 95% CI for patients treated with aCT were 1.25(0.68-2.29), 0.58(0.37-0.89) and 0.83(0.66-1.10) for patients with pCR, ypT1-2 and ypT3-4 tumours, respectively. The effect of aCT in rectal cancer patients treated with CRT differs between subgroups. Patients with a pCR after CRT may not benefit from aCT, whereas patients with residual tumour had superior outcomes when aCT was administered. The test for interaction did not reach statistical significance, but the results support further investigation of a more individualized approach to administer aCT after CRT and surgery based on pathologic staging.

KW - adjuvant chemotherapy

KW - neoadjuvant treatment

KW - rectal cancer

KW - response

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84930416461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930416461&partnerID=8YFLogxK

U2 - 10.1002/ijc.29355

DO - 10.1002/ijc.29355

M3 - Article

C2 - 25418551

AN - SCOPUS:84930416461

VL - 137

SP - 212

EP - 220

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -